Depression in schizophrenia, can it be treated? A review of the evidence

Current Psychiatry Reviews

Volumn 2, Issue 3, 2006, Pages 371-379

  Ramírez, Nicolás ^a   Arranz, Belén ^b   Sánchez, José ^c   Centeno, Meritxell ^d   San, Luis ^a  

^a HOSPITAL SAN RAFAEL   (Spain)

^b CSS Palau   (Spain)

^c Department of Psychiatry   (Spain)

^d HOSPITAL GENERAL DE GRANOLLERS   (Spain)

Author keywords

Antidepressants; Depression; Extrapyramidal symtoms; Negative symtoms; Schizophrenia; Second generation antipsychotics

Indexed keywords

AMITRIPTYLINE; ANTIDEPRESSANT AGENT; ANTIHYPERTENSIVE AGENT; ANTINEOPLASTIC AGENT; BENZODIAZEPINE DERIVATIVE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CITALOPRAM; CLOZAPINE; CORTICOSTEROID; FLUOXETINE; FLUPHENAZINE; FLUPHENAZINE DECANOATE; FLUVOXAMINE; HALOPERIDOL; HYPNOTIC AGENT; IMIPRAMINE; MOLINDONE; NEUROLEPTIC AGENT; OLANZAPINE; PAROXETINE; PERAZINE; QUETIAPINE; REBOXETINE; RISPERIDONE; SERTRALINE; THIORIDAZINE; TRICYCLIC ANTIDEPRESSANT AGENT; TRIMIPRAMINE; UNINDEXED DRUG; ZIPRASIDONE;

AKATHISIA; AKINESIA; ALCOHOLISM; ASTHENIA; CANNABIS ADDICTION; CLINICAL TRIAL; COGNITIVE DEFECT; DEPRESSION; DIFFERENTIAL DIAGNOSIS; DISEASE EXACERBATION; DRUG BLOOD LEVEL; DRUG COMPETITION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG METABOLISM; DRUG RESPONSE; EVIDENCE BASED MEDICINE; EXTRAPYRAMIDAL SYMPTOM; HUMAN; HYPOMANIA; MANIA; NEGATIVE SYNDROME; POSITIVE SYNDROME; PRIORITY JOURNAL; PROGNOSIS; PSYCHOSOCIAL REHABILITATION; PSYCHOTHERAPY; REVIEW; SCHIZOPHRENIA; SEROTONIN SYNDROME;

EID: 33747650429     PISSN: 15734005     EISSN: None     Source Type: Journal    
DOI: 10.2174/157340006778018175     Document Type: Review

References (74)

1. Shelton RC. Treatment options for refractory depression. J Clin Psychiatry 1999; 60: 57-61.
2. Koreen AR, Siris SG, Chakos M, Alvir J, Mayerhoff D, Lieberman J. Depression in first-episode schizophrenia. Am J Psychiatry 1993; 150: 1643-8.
3. Siris SG. Depression in Schizophrenia. In: Shriqui CL, Nasrallah HA (Ed). Contemporary Issues in the treatment of schizophrenia. Washington: American Psychiatry Press; 1995.
4. Lancon C, Auquier P, Reine G, Bernard D, Addington D. Relationships between depression and psychotic symptoms of schizophrenia during an acute episode and stable period. Schizophr Res 2001; 47: 135-40.
5. Johnson DA. The significance of depression in the prediction of relapse in chronic schizophrenia. Br J Psychiatry 1988; 152: 320-3.
6. Addington D, Addington J, Patten S. Depression in people with first-episode schizophrenia. Br J Psychiatry 1998; 172(Suppl): 90-2.
7. Emsley RA, Oosthuizen MB, Joubert AF, Roberts MC, Stein DJ. Depressive and anxiety symptoms in patients with schizophrenia and schizophreniform disorder. J Clin Psychiatry 1999; 60: 747-51.
8. Nordentoft M, Jeppesen P, Abel M, et al. OPUS study: suicidal behaviour, suicidal ideation and hopelessness among patients with fast-episode psychosis. One-year follow-up of a randomized controlled trial. Br J Psychiatry 2002; 43(Suppl): 98-106.
9. Birchwood M. Depression and suicidal thinking in psychosis: a cognitive approach. In: Wykes T, Tarrier N, Lewis S, eds. Outcome and Innovation in Psychological Treatment of Schizophrenia. Chichester: John Wiley & Sons Ltd; 1998: 81-100.
10. Ram R, Jandorf L, Dixon L, Bromet E. Depressive syndromes in first admission patients with schizophrenic disorders: the extent, phenomenology, correlates and change over six months. Schizophr Res 1995; 15: 1-2.
11. Heila H, Isometsa ET, Henrikson MM, Heikkinen ME, Marttunen MJ, Lonnqvist JK. Suicide and schizophrenia: a nationwide psychological autopsy study on age- and sex-specific clinical characteristics of 92 suicide victims with schizophrenia. Am J Psychiatry 1997; 154: 1235-42.
12. Fenton WS, McGlashan TH, Victor BJ, Blyler CR. Symptoms, subtype, and suicidality in patients with schizophrenia spectrum disorders. Am J Psychiatry 1997; 154: 199-204.
13. Müller-Seicheneder F, Müller MJ, Hillert A, Szegedi A, Wetzel H, Benkert O. Risperidone versus haloperidol and amitryptiline in the treatment of patients with a combined psychotic and depressive syndrome. J Clin Psychopharmacol 1998; 18: 111-20.
14. Becker RE, Singh MM, Meisler N, Shillcutt S. Clinical significance, evaluation, and management of secondary depression in schizophrenia. J Clin Psychiatry 1985; 46: 26-32.
15. Petit M. Antidepressive drug treatment of the schizophrenic patient. Encephale 1994; 20: 667-74.
16. Lam RW, Peters R, Sladen-Dew N, Altman S. A comunity-based clinic survey of antidepressant use in persons with schizophrenia. Can J Psychiatry 1998; 43: 513-6.
17. Bartels SJ, Drake RE. Depressive symptoms in schizophrenia: comprehensive differential diagnosis. Compr Psychiatry 1988; 29: 467-83.
18. Siris SG. Depression in schizophrenia: perspective in the era of "atypical" antipsychotic agents. Am J Psychiatry 2000; 157: 1379-89.
19. Mulholland C, Cooper S. The symptom of depression in schizophrenia and its management. Adv Psychiatr Treatment 2000; 6: 169-77.
20. Hogarty GE, McEvoy JP, Ulrich RF, et al. Pharmacotherapy of impaired affect in recovering schizophrenic patients: Arch Gen Psychiatry 1995; 52: 29-41.
21. Hirsch SR, Jolley AG, Barnes TR, et al. Dysphoric and depressive symptoms in chronic schizophrenia. Schizophr Res 1989; 2: 259-64.
22. Tate JL. Extrapyramidal symptoms in a patient taking haloperidol and fluoxetine. Am J Psychiatry 1989; 146: 399-400.
23. Carpenter WT, Jr., Heinrichs DW, Wagman AM. Deficit and nondeficit forms of schizophrenia: the concept. Am J Psychiatry 1988; 145: 578-83.
24. Carpenter WT, Jr. The treatment of negative symptoms: pharmacological and methodological issues. Br J Psychiatry 1996; 29(Suppl): 17-22.
25. Möller HJ, Muller H, Borison R, Schooler NR, Chouinard G. A path analytical approach to differentiate between direct and indirect drug effects on negative symptoms in schizophrenic patients: a re-evaluation of the North American risperidone study. Eur Arch Clin Neurosci 1995; 245: 45-9.
26. Tollefson GD, Sanger TM. Negative symptoms: a path analytic approach to a double-blind, placebo and haloperidol controlled clinical trial with olanzapine. Am J Psychiatry 1997; 154: 466-74.
27. Lindenmayer JP, Czobor P, Volvka J, et al. Effects of atypical antipsychotics on the syndromal profile in treatment-resistant schizophrenia. J Clin Psychiatry 2004; 65: 551-6.
28. Silver H, Aarón N, Kaplan A. Add-on fluvoxamine improves primary negative symptoms: evidence for specificity from response analysis of individual symptoms. Schizophr Bull 2003; 29: 541-6.
29. Goff DC, Midha KK, Sarid-Segal O, Hubbard JW, Amico E. A placebo-controlled trial of fluoxetine added to neuroleptic in patients with schizophrenia. Psychopharmacol 1995; 117: 417-23.
30. Tapp A, Kilzieh N, Wood AE, Raskind M, Tandon R. Depression in patients with schizophrenia during an acute psychotic episode. Compr Psychiatry 2001; 42: 314-8.
31. Ramírez N, Sarro S, Arranz B, Sanchez JM, González JM, San L. Instruments of depression assessment in schizophrenia. Actas Esp P siquiatr 2001; 29(4): 259-268.
32. Plasky P. Antidepressant usage in schizophrenia. Schizophr Bull 1991; 17: 649-57.
33. Dollfus S, Petit M, Menard JF. Relationship between depressive and positive symptoms in schizophrenia. J Affect Disord 1993; 28: 61-9.
34. Levinson DF, Umapathy C, Musthaq M. Treatment of schizoaffective disorder and schizophrenia with mood symptoms. Am J Psychiatry 1999; 156: 1138-48.
35. Kramer MS, Vogel WH, DiJohnson C, et al. Antidepressants in 'depressed' schizophrenic inpatients. A controlled trial. Arch Gen Psychiatry 1989; 46: 922-8.
36. Dufresne RL. Issues in polypharmacotherapy: focus on depression in schizophrenia. Psychopharmacol Bulletin 1995; 31: 789-96.
37. American Psychiatric Association. Practice guidelines for the treatment of patients with schizophrenia. Am J Psychiatry 1997; 154(suppl): 1-63.
38. Whitehead C, Moss S, Cardno A, Lewis G. Antidepressants for the treatment of depression in people with schizophrenia: a systematic review. Psychol Med 2003; 33: 589-99.
39. Bender S, Olbrich HM, Fischer W, et al. Trimipramine Study Group. Antipsychotic efficacy of the antidepressant trimipramine: a randomized, double-blind comparison with the phenothiazine perazine. Pharmacopsychiatry 2003; 36: 61-9.
40. Siris SG, Mason SE, Bermanzohn PC, Alvir JM, McCorry TA. Adjunctive imipramine maintenance in post-psychotic depression/negative symptoms. Psychopharmacol Bull 1990; 26: 91-4.
41. Siris SG, Bermazohn PC, Mason SE, Shuwall MA. Maintenance imipramine therapy for secondary depression in schizophrenia. Arch Gen Psychiatry 1994; 51: 109-15.
42. Goff DC, Brotman AW, Waites M, McCormick S. Trial of fluoxetine added to neuroleptics for treatment-resistant schizophrenic patients. Am J Psychiatry 1990; 147: 492-4.
43. Caroli F, Baldacci-Epinette C, Ribeyre P. Antidepressant treatment of schizophrenic patients. Encephale 1993; 19: 393-6.
44. Mulholland C, Lynch G, Cooper SJ, King DJ. A double-blind, placebo-controlled trial of sertraline for depressive symptoms in stable, chronic schizophrenia. Biol Psychiatry 1997; 42(suppl 1): 188.
45. Kasckow JW, Mohamed S, Thallasinos A, Carroll B, Zisook S, Jeste DV. Citalopram augmentation of antipsycotic treatment in older schizophrenia patients. Inn J Geriatr Psychiatry 2001; 16: 1163-7.
46. Salokangas RKR, Saarijäri S, Taiminen T, et al. Citalopram as an adjuvant in chronic schizophrenia: a double-blind placebo-controlled study. Acta Psychiatr Scand 1996; 94: 175-80.
47. Schutz G, Berk M. Reboxetine add on therapy to haloperidol in the treatment of schizophrenia: a preliminary double-blind randomized placebo-controlled study. Int Clin Psychopharmacol 2001; 16: 275-8.
48. Spina E, Avenoso A, Salemi M, et al. Plasma concentrations of clozapine and its major metabolites durig combined treatment with paroxetine or sertraline. Pharmacopsychiatry 2000; 33: 213-7.
49. Harrow M, Yonan CA, Sands JR, Marengo J. Depression in schizophrenia: are neuroleptics, akinesia or anhedonia involved? Schizophr Bull 1994; 20: 327-38.
50. Hamilton S, Malone K. Serotonin syndrome during treatment with paroxetine and risperidone. J Clin Psychopharmacol 2000; 20: 103-5.
51. Siris SG, Sellew AP, Prechen K, Cooper TB, Mandel J, Casey E. Antidepressant in the treatment of post-psychotic depression in schizophrenia: drug interactions and other considerations. Clin Chem 1988; 34: 837-40.
52. Dufresne RL, Valentino D, Kass DJ. Thioridazine improves affective symptoms in schizophrenic patients. Psychopharmacol Bull 1993; 29: 249-55.
53. Keck P, Strakowski SM, McElroy SL. The efficacy of atypical antipsychotics in the treatment of depressive symptoms, hostility, and suicidality in patients with schizophrenia. J Clin Psychiatry 2000; 61(suppl 3): 4-9.
54. Aubry JM, Simon AE, Bertschy G. Possible inductionn of mania and hypomania by olanzapine and risperidone: a critical review of reported cases. J Clin Psychiatry 2000; 61: 649-55.
55. Biancosino B, Marmai L, Facchi A, Rossi E, Grassi L. Quetiapine may induce mania: a case report. Can J Psychiatry 2003; 48: 349-50.
56. Mishra A, Moore PB, Hobbs R. Does quetiapine have mood altering properties? J Psychopharmacol 2004; 18: 281-4.
57. McElroy SL, Dessain EC, Pope HG Jr, et al. Clozapine in the treatment of psychotic mood disorders, schizoaffective disorder, and schizophrenia. J Clin Psychiatry 1991; 52: 411-4.
58. Walker AM, Lanza LL, Arellano F, Rothman KJ. Mortality in current and former users of clozapine. Epidemiology 1997; 8: 671-7.
59. Meltzer HY, Okayli G. Reduction of suicidality during clozapine treatment of neuroleptic-resistant schizophrenia: impact on risk-benefict assessment. Am J Psychiatry 1995; 152: 183-90.
60. Marder SR, Meibach RC. Risperidone in the treatment of schizophrenia. Am J Psychiatry 1994; 151: 825-35.
61. Marder SR, Davis JM, Chouinard G. The effects of risperidone on the five dimensions of schizophrenia derived by factor analysis: combined results of the North American trials. J Clin Psychiatry 1997; 58: 538-46.
62. Peuskens J. Risperidone in the treatment of patients with chronic schizophrenia: a multinational, multi-center, double-blind, parallel group study versus haloperidol. Br J Psychiatry 1995; 166: 712-26.
63. Ceskova E, Svestka J. Double-blind comparison of risperidone and haloperidol in schizophrenic and schizoaffective psychosis. Pharmacopsychiatry 1993; 26: 121-4.
64. Tollefson GD, Sanger TM, Lu Y, Thieme ME. Depressive signs and symptoms in schizophrenia: a prospective blinded trial of olanzapine and haloperidol. Arch Gen Psychiatry 1998; 55: 250-8.
65. Lane HY, Guo SC, Hwang TJ, et al. Effects of olanzapine plasma concentrations on depressive symptoms in schizophrenia: a pilot study. J Clin Psychopharmacol 2002; 22: 530-2.
66. Keck P, Buffenstein A, Ferguson J, et al. Ziprasidone 40 and 120 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a 4-week placebo-controlled trial. Psychopharmacol 1998; 140: 173-84.
67. Khouzam HR. Treatment of depressive mood in schizophrenia with the atypical antipsychotic quetiapine. Depress Anxiety 2000; 11: 80-2.
68. Emsley RA, Buckley P, Jones AM, Greenwood MR. Differential effect of quetiapine on depressive symptoms in patients with partially responsive schizophrenia. J Psychopharmacol 2003; 17: 210-15.
69. Kotler M, Strouss RD, Reznik I, Shwartz S, Weizman A, Spivak B. Sulpiride augmentation of olanzapine in the management of treatment-resistant chronic schizophrenia: evidence for improvement of mood symptomatology. Int Clin Psychopharmacol 2004; 19: 23-6.
70. Mauri MC, Bitetto A, Fabiano L, et al. Depressive symptoms and schizophrenic relapses: the effect of four neuroleptic drugs. Prog Neuro-Psychopharmacol 1999; 23: 43-54.
71. Lerner Y, Mintzer Y, Schestazky M. Lithium combined with haloperidol in schizophrenia patients. Br J Psychiatry 1988; 153: 359-62.
72. Christisson GW, Kirch DG, Wyatt RJ. When symptoms persist: choosing among alternative somatic treatments for schizophrenia. Schizophr Bull 1991; 17: 217-40.
73. Atre-Vaidya N, Taylor MA. Effectiveness of lithium in schizophrenia: do we really have a answer? J Clin Psychiatry 1989; 50: 170-3.
74. Hogarty GE, Anderson CM, Reiss DJ, et al. Family psycho-educational, social skills training and maintenance chemotherapy in the aftercare treatment of schizophrenia, 1: one-year effects of a controlled study on relapse and expressed emotion. Arch Gen Psychiatry 1986; 43: 633-42.